Skip to main content
Google Tag Manager
P&T COMMUNITY
Search form
Search
News
Approvals, Launches, & New Indications
Pipeline Plus
Research News
Industry Trends
Safety Issues
Agency Actions
Health Care Reform
Guidelines
Clinical Trials
P&T
Current issue
Past issues
Digital Edition
Subscribe
P&T TV
Dr. David B. Nash
Meeting Reports
Health Care & Law
Drug Forecast
More
Meeting Highlights
Medication Errors
Prescription: Washington
About
News
P&T Journal
You are here
Home
News by month %2 2017
News by month October 2017
PTCommunity News October 2017
FDA Approves New Treatment for Mantle Cell Lymphoma
Study: Lethal Dangers Lurk Even After Opioid Overdose Rescue
Drug-Pricing Watchdog Gets Funding to Expand Efforts
Companies, Medications Added in Generic-Drug Antitrust Suit
Positive Phase 3 Results for Dupilumab in Severe Steroid-Dependent Asthma
U.S. Moves to Revoke Claim That Soy Protein Protects the Heart
FDA Approves New Dosing for Rivaroxaban to Reduce the Continued Risk of Venous Thromboembolism
Orphan Drug Designation Granted to MM-121 for the Treatment of Heregulin-Positive Non–Small-Cell Lung Cancer
New Data: Children and Adolescents With MS Had an 82% Lower Relapse Rate With Fingolimod
Haegarda Shows 98% Median Reduction in Hereditary Angioedema Attacks Per Month in Study
Intravenous Formulation of Varubi Wins FDA Approval
Breakthrough Therapy Status for Hemophilia A Treatment
ACIP Recommends Shingrix Over Zostavax to Prevent Shingles
FDA Won’t Approve Ataluren; PTC Therapeutics to Appeal
Cholesterol Levels Falling Among U.S. Adults, CDC Says
FDA Slams Magellan Diagnostics for Lead Testing Violations
Ingrezza Given Orphan Drug Status for Tourette Syndrome in Young
MOR208 Named a “Breakthrough Therapy” in Some Lymphoma Cases
FDA Approves Shingles Vaccine With More Than 90% Efficacy
Easier-to-Use Formulation of Bydureon Wins FDA’s Blessing
African-Americans Die Younger Due to Heart Disease, Stroke
Biosimilars Could Cut U.S. Health Tab by $54 Billion in a Decade
Simponi Aria Approved for Psoriatic Arthritis, Ankylosing Spondylitis
FDA Approves Yescarta, First CAR T-Cell Therapy for Lymphoma
Anthem to Launch New Pharmacy Benefits Manager
Imprimis to Offer Compounded Alternative to Restasis
Nonopioid Drug Helps Migraines More Than Opioids, Study Shows
Keytruda Doubles Lung Cancer Survival in Patients With High PD-L1
Marino Withdraws From Consideration as U.S. Drug Czar
U.S. Judge Invalidates Allergan Patents on Restasis
Study: Emergency Rooms Provide Nearly Half of Medical Care
Cascade of Costs Could Push Gene Therapy Over $1 Million Per Patient
Trial Shows Strong Response to Lorlatinib in NSCLC Patients
Cabozantinib Improves Survival in Advanced Liver Cancer
FDA Clears Robotically-Assisted Surgical Device for Adults
Stelara Approved for Use in Adolescents With Plaque Psoriasis
NIH, Big Pharma Launch Cancer Immunotherapy Drive
FDA Clears First 7T Magnetic Resonance Imaging Device
Penicillin Misconceptions May Lead to Surgical Infections
Study Finds Few Medicare Limits on Prescription Opioids
Lilly Dealt a Setback by Phase 3 Lung Cancer Results
Vaccine Receives Orphan Drug Designation for Brain Cancer
Pfizer Weighs “Strategic Alternatives” for Consumer Healthcare Business
Tagrisso Termed Breakthrough Therapy as Initial Lung Cancer Treatment
Zilretta Approved for Osteoarthritis Knee Pain
FDA Approves Implantable Sleep Apnea Treatment
SenTiva Approved for Treatment of Epilepsy
FDA Approves First Zika Screening Test for Blood Donations
U.S. Appeals Court Reverses Ban on Praluent Sales
Antibiotic Susceptibility Testing in 30 Minutes or Less?
DNA-Based Zika Vaccine Safe, Effective in Phase 1 Testing
Mylan’s Generic of Copaxone Receives FDA Approval
Oxford Team to Test First Universal Flu Vaccine
Cancers Associated With Excess Weight Make Up 40% of U.S. Cancer Cases
Antifungal Drug Candidate Receives Second QIDP Designation
Study: Patient Expectations Influence Effectiveness of SSRI Antidepressants
Study: Sepsis Care Initiatives May Increase C. Difficile Rates, Antibiotic Resistance
FDA Seeks to Reduce Hurdles for Complex Generic Drug Development
FDA Gives Adcetris Breakthrough Therapy Status as Firstline Hodgkin’s Treatment
Merck Becomes Latest to Drop HCV Development Programs
No Link Between Drug Safety in U.S. and Approval Speed, According to Tufts Center for the Study of Drug Development
Phase 3 Trial of Ocinaplon Placed on Hold
